Share on StockTwits
 

Investment analysts at CRT Capital upped their price objective on shares of Actavis (NYSE:ACT) from $210.00 to $230.00 in a note issued to investors on Wednesday, AnalystRatingsNetwork.com reports. The firm currently has a “buy” rating on the stock. CRT Capital’s price objective suggests a potential upside of 14.16% from the stock’s previous close.

Other equities research analysts have also recently issued reports about the stock. Analysts at Bank of America set a $235.00 price target on shares of Actavis in a research note on Wednesday. They now have a “buy” rating on the stock. Separately, analysts at Buckingham Research raised their price target on shares of Actavis from $210.00 to $250.00 in a research note on Wednesday. Finally, analysts at Goldman Sachs upgraded shares of Actavis from a “neutral” rating to a “buy” rating in a research note on Wednesday. They now have a $250.00 price target on the stock, up previously from $185.00. Five equities research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company. Actavis currently has a consensus rating of “Buy” and an average price target of $189.82.

Actavis (NYSE:ACT) traded up 4.69% on Wednesday, hitting $210.92. 5,933,901 shares of the company’s stock traded hands. Actavis has a 1-year low of $82.02 and a 1-year high of $208.75. The stock has a 50-day moving average of $182.5 and a 200-day moving average of $156.7. The company’s market cap is $36.700 billion.

Actavis, Inc formerly Watson Pharmaceuticals, Inc, is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (NYSE:ACT) pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.